CBU
NBIX icon

CIBC Bancorp USA’s Neurocrine Biosciences NBIX Stock Holding History

CIBC Bancorp USA’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813K Sell
4,821
-28
-0.6% -$4.15K ﹤0.01% 1153
2026
Q1 		$639K Buy
+4,849
New +$643K ﹤0.01% 1156
2025
Q3 		$498K Buy
+3,548
New +$481K ﹤0.01% 875

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CIBC Bancorp USA's NBIX Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Neurocrine Biosciences (NBIX) stake by 0.58% in Q2 2026, selling an estimated $4.15K and leaving 4,821 shares worth $813K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

CIBC Bancorp USA first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CIBC Bancorp USA held 4,821 shares of Neurocrine Biosciences worth $813K as of Q2 2026.
  • CIBC Bancorp USA sold 28 Neurocrine Biosciences shares in Q2 2026, an estimated $4.15K.
  • Neurocrine Biosciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1153 holding.
  • CIBC Bancorp USA first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.